PRRT2 and stage 5 chronic kidney disease: has been demonstrated to activate various signalling pathways, including PKC, MAPK, JAK-STAT, and the hexosamine pathway, ultimately leading to increased glomerular extracellular matrix, cellular senescence, apoptosis, inflammation, tubulointerstitial fibrosis, and progression to end-stage renal disease [13, 21].